Related Experiment Video
Updated: Nov 10, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
JNK and p38 Inhibitors Prevent Transforming Growth Factor-β1-Induced Myofibroblast Transdifferentiation in Human
Tzu-Yu Hou1,2,3, Shi-Bei Wu4, Hui-Chuan Kau1,2,3,5
1Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Abstract:
Transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from orbital fibroblasts is known to dominate tissue remodeling and fibrosis in Graves' ophthalmopathy (GO). However, the signaling pathways through which TGF-β1 activates Graves' orbital fibroblasts remain unclear. This study investigated the role of the mitogen-activated protein kinase (MAPK) pathway in TGF-β1-induced myofibroblast transdifferentiation in human Graves' orbital fibroblasts. The MAPK pathway was assessed by measuring the phosphorylation of p38, c-Jun N-terminal kinase (JNK), and extracellular-signal-regulated kinase (ERK) by Western blots. The expression of connective tissue growth factor (CTGF), α-smooth muscle actin (α-SMA), and fibronectin representing fibrogenesis was estimated. The activities of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) responsible for extracellular matrix (ECM) metabolism were analyzed. Specific pharmacologic kinase inhibitors were used to confirm the involvement of the MAPK pathway. After treatment with TGF-β1, the phosphorylation levels of p38 and JNK, but not ERK, were increased. CTGF, α-SMA, and fibronectin, as well as TIMP-1 and TIMP-3, were upregulated, whereas the activities of MMP-2/-9 were inhibited. The effects of TGF-β1 on the expression of these factors were eliminated by p38 and JNK inhibitors. The results suggested that TGF-β1 could induce myofibroblast transdifferentiation in human Graves' orbital fibroblasts through the p38 and JNK pathways.
Insights
Transforming growth factor-β1 (TGF-β1) activates Graves
Area of Science:
- Ophthalmology
- Cell Biology
- Molecular Biology
Background:
- Graves' ophthalmopathy (GO) involves tissue remodeling and fibrosis driven by transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation.
- The precise signaling pathways mediating TGF-β1 activation of orbital fibroblasts in GO are not fully understood.
Purpose of the Study:
- To investigate the role of the mitogen-activated protein kinase (MAPK) pathway in TGF-β1-induced myofibroblast transdifferentiation in human Graves' orbital fibroblasts.
Main Methods:
- Western blots were used to measure the phosphorylation of p38, c-Jun N-terminal kinase (JNK), and extracellular-signal-regulated kinase (ERK).
- Expression of fibrogenic markers (CTGF, α-SMA, fibronectin) and extracellular matrix (ECM) regulators (MMPs, TIMPs) was analyzed.
- Pharmacologic kinase inhibitors targeting the MAPK pathway were employed to validate findings.
Main Results:
- TGF-β1 treatment increased phosphorylation of p38 and JNK, but not ERK.
- Fibrogenic markers (CTGF, α-SMA, fibronectin) and TIMP-1/TIMP-3 were upregulated, while MMP-2/-9 activity decreased.
- Inhibition of p38 and JNK pathways abolished TGF-β1-induced changes in marker expression.
Conclusions:
- TGF-β1 induces myofibroblast transdifferentiation in human Graves' orbital fibroblasts.
- The p38 and JNK signaling pathways are critical mediators of this TGF-β1-induced process.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Forced Transdifferentiation
Artificial...
Introduction to Fibroblasts

